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Summary 
Objectives: To set the scientific context and then suggest principles for an evidence-based 
approach to secondary uses of clinical data, covering both evaluation of the secondary uses of 
data and evaluation of health systems and services based upon secondary uses of data. 
Method: Working Group review of selected literature and policy approaches. 
Results: We present important considerations in the evaluation of secondary uses of clinical 
data from the angles of governance and trust, theory, semantics, and policy. We make the 
case for a multi-level and multi-factorial approach to the evaluation of secondary uses of 
clinical data and describe a methodological framework for best practice. We emphasise the 
importance of evaluating the governance of secondary uses of health data in maintaining the 
trust, which is essential for such uses. We also offer examples of the re-use of routine health 
data to demonstrate how it can support evaluation of clinical performance and optimize 
health IT system design. 
Conclusions: Great expectations are resting upon “Big Data” and innovative analytics. 
However, to build and maintain public trust, improve data reliability, and assure the validity 
of analytic inferences, there must be independent and transparent evaluation. A mature and 
evidence-based approach needs not merely data science, but must be guided by the broader 
concerns of applied health informatics. 
 
Keywords: Data mining; Secondary use; Informed consent; Evidence-based practice; 
Program evaluation. 
  
1. Introduction 
In this contribution, the IMIA working group on Technology Assessment & Quality 
Development in Health Informatics offers some evaluation considerations for secondary uses 
of clinical data. In setting out important principles for an evidence-based approach to policy 
and implementation, we identify two quite distinct conceptual categories of concern: first, 
evaluation of the secondary uses of data from philosophical, methodological, and ethical 
perspectives; and second, evaluation of health systems and services based upon secondary 
uses of data. 
‘Secondary use’ needs definition. Simply put, ‘Secondary use of health data applies personal 
health information for uses outside of direct health care delivery’ [2]. Data is recorded for a 
particular purpose within a healthcare encounter, such as recording presenting problems, 
tentative diagnosis, and treatment action initiated. Few would argue against using that data to 
track an antigen batch, to audit quality of delivery, or to deal with a subsequent complaint, 
even though these were not anticipated at the time of recording.  Secondary use is when data 
recorded for an operational care purpose is used to create new intelligence or knowledge 
away from its context of origin and without the originators necessarily being aware. 
Examples include: clinical research, population health, epidemiology, and pharmaceutical 
effectiveness. Specific lines of research may include policy effectiveness (achieving 
objectives); treatment outcomes against intent; multi-morbidity patterns; polypharmacy 
outcomes; changing illness patterns. Though potential sources of data may appear 
homogeneous, such as hospital records, the components and resultant analyses are very 
varied and focussed. The potential scope may include laboratory data, pharmacy, radiology, 
immunisation, emergency/elective attendances, primary care, mental health, social care, 
payers, public health, bio-surveillance, pharmacovigilance, and incident reporting, while 
external linkages to enable greater depth of interpretation in a big data modality may include 
census data, meteorological data, law enforcement data, education data, and housing data. 
To set the scene, we highlight the fact that there are different aggregations and resultant 
analysis of big data sets. In the commercial world, ‘big data’ may be seen as the aggregation 
of data from disparate unrelated sources. For instance, data might be combined from 
consumer spending recorded on loyalty cards, weather forecasts, small area socio-economic 
profiling, and television schedules to forecast product demand for supermarket branches to 
drive the supply chain. By contrast, most large health data sets are of similar data set types, 
such as pooled anonymised primary care consultation and prescribing data to look at long 
term outcomes. Increasingly, however, the health sector focus is on what might be called 
‘hybrid’ large data sets, where different health data sets are analysed together. Far more than 
commercial ‘big data’, ‘hybrid’ health data faces ethical and governance issues and questions 
of public trust and acceptability. There are both practical and public perception issues about 
re-use that take very different and operationally unlinked data together in analyses to seek 
new and unanticipated forms of personal behaviour, illness trajectories, and likely outcomes. 
Timely and accurate health data spanning the continuum of care linked at patient level, and 
safely shared as necessary for care delivery purposes, has been recognized globally as an 
essential tool. Secondary use is seen as critical not just for the optimal delivery of individual 
health care interventions, but also for improving performance of health care systems and 
health outcomes of patients, for obtaining longer-term and real world evaluations of existing 
treatments including in a multi-morbidity context, for supporting the re-design and evaluation 
of new models of health care service delivery and for contributing to the discovery and 
evaluation of new treatments [1]. This is the foundation of both Smarter Healthcare [3, 4] and 
Learning Health Systems [5].  
This means there is a need for an evidence-based approach: balancing innovation and 
evaluation with trust and governance. This results in the need for an evaluation lifecycle of 
secondary analysis, with both formative and summative elements [6, 7]. This would build 
trust, support accountability, transparency and regulation; and have as one requirement 
transparent reporting of the evaluation of secondary use analyses. 
This paper starts with the first conceptual category introduced above, evaluation of secondary 
uses of data. Sections two and three address evaluation issues from the perspectives of 
governance, trust, theoretical considerations, semantics, and context. Then we consider, in 
section four, how national and regional policies are framing evaluation factors relevant to 
secondary uses (both of secondary uses and based upon secondary uses). Section five 
presents examples of how the analysis based upon secondary uses has informed 
enhancements in clinical performance and health IT design. Finally, section six synthesises 
the two categories and demonstrates why a multi-level evaluation approach is needed. We 
conclude with summary recommendations. 
2. Governance and Trust 
Anxiety about health information confidentiality is an issue for many patients and care 
professionals, particularly when data are collected digitally and held virtually. Managing safe 
use of health data is a major concern across the Organisation for Economic Co-operation and 
Development (OECD) countries, having a direct impact on the sharing of personal health 
data, and even causing patients to engage in “privacy protective behaviours” (avoiding 
screening tests, treatment, or be recruited in research protocols). The development and 
publication of suitable policies or guidelines greatly increases public transparency [1, 5]. 
The possibility of wide secondary use, for reasons and by agencies not known at the time of 
data collection, and without individual permission at the time of analysis, raises a multiplicity 
of new concerns about personal confidentiality and about the exploitation of knowledge for 
unknown purposes. Uncontrolled use for secondary purposes may thus lead to greater 
anxiety, greater potential for protective behaviours, and thereby also for incomplete and 
biased data sets [8]. Conversely, however, undue restriction on controlled secondary use 
closes down important research options without society having opportunity to debate this 
potential non-discovery of new knowledge. 
These concerns could be magnified by the push towards “open data” [9, 10], even though 
data is intended to be aggregate and non-identifiable. However, a recent study of 13,000 US 
biobank participants reported that although 51% expressed worry about privacy, results did 
not suggest that open data sharing would adversely affect participant recruitment [11]. Given 
that biobank participation is based on the explicit consent of some kind, this finding is not 
necessarily transferable to routine secondary use of “open data” from the general population. 
Indeed, a recent survey of over 20,000 citizens from across the European Union (EU) found a 
strong preference for not sharing anonymised health data with academic researchers [12]. 
A particular privacy concern relates to re-identification of “anonymised” data. Privacy 
legislation allows the disclosure of health data for secondary purposes without patient consent 
if the data are de-identified. De-identification is the act of reducing the information content in 
data to decrease the probability of discovering an individual's identity. It has been argued that 
de-identification methods do not provide sufficient protection because they are easy to 
reverse and thus data can be easily re-identified. However, a systematic review [13] showed 
that only a few attacks have involved health data and more importantly, most re-identified 
data has not been de-identified according to existing standards. 
To manage the harmful risks of re-identification, future research should focus on re-
identification attacks on large databases that have been de-identified following existing 
standards, and success rates should be correlated with how well de-identification was 
performed. It is important to collect an evidence-based understanding of the extent to which 
de-identification standards and practices protect against real re-identification attacks and how 
the standards and practices should be developed to cover the future challenges. Given that “it 
can be impossible to assess re-identification risk with absolute certainty” [14], this and other 
citizen concerns demand open and transparent debate. Scotland is an example of a country 
which has sought open debate on local approaches, and made clear its policies [15]. 
Good governance is therefore an essential prerequisite for ensuring effective primary and 
secondary use of health IT systems. It provides a framework to create the necessary trust to 
enable full and willing secondary, or value-adding, use [1]. A definition of governance [16] 
specifies monitoring and evaluation as an integral part of any policy, and e-health is no 
exception. Developing and implementing national e-health strategies calls for monitoring and 
assessing their progress towards availability, usability, quality, and integrity of the data, and 
its safe sharing ability and transparency – data governance [17]. Evaluation is essential to 
identify good practices from which others could learn to support the movement toward 
common best practices [1]. 
The OECD has a long-standing interest and expertise in this area and has published eight key 
data governance mechanisms to support strengthening national health information systems 
and enabling multi-country projects to improve the population health (Box 1). Each of these 
calls for some kind of assessment and evaluation.   
 Box 1: OECD key data governance mechanisms 
Provision of good quality personal health data is a prerequisite for extracting good quality 
statistics for secondary use purposes, but it is merely a beginning. There is still much work 
needed to develop criteria and assess maturity of individual countries’ data governance 
systems related to secondary use of health data. Ensuring trust through conspicuous and 
transparent governance frameworks is an essential prerequisite. Sound examples exist, and 
continued evaluation is necessary to refine best and most effective practice. 
3. Theoretical considerations, semantics, and context 
Secondary use of clinical data carries several fairly obvious assumptions, all of which are 
fundamental to inferential statistics, but the limitations of which are not always 
acknowledged in the way health data are used or abused. Firstly, it is frequently believed that 
it is theoretically valid to re-use data outside their context of origination and that meaning can 
be safely asserted independently of that context. Secondly, it must be assumed that 
operational clinical data are of sufficient minimum quality to be reliable and usable (albeit 
with various “data cleansing” procedures required). Thirdly, it is held that sound population-
1.         The health information system supports the monitoring and improvement of 
health care quality and system performance, as well as research innovations for better 
health care and outcomes. (There are indicators in the OECD e-health model survey 
for organisations to measure attainment of this principle.) 
2.         The processing and the secondary use of data for public health, research, and 
statistical purposes are permitted, subject to safeguards specified in the legislative 
framework for data protection. (This principle calls for evaluation of national 
policies and legislation.) 
3.         The public is consulted upon and informed about the collection and 
processing of personal health data. (Existence of this mechanism calls for policy 
analysis; public awareness can be monitored by citizen surveys.) 
4.         A certification/accreditation process for the processing of health data for 
research and statistics is implemented.  
5.         The project approval process is fair and transparent, and decision-making is 
supported by an independent, multidisciplinary, project review body.  
6.         Best practices in data de-identification are applied to protect patient data 
privacy.  
7.         Best practices in data security and management are applied to reduce re-
identification and breach risks.  
8.         Governance mechanisms are periodically reviewed at an international level to 
maximise societal benefits and minimise societal risks as new data sources and new 
technologies are introduced (see [1] section 5.1). 
level inferences can be drawn from such secondary use of data. In this section, we examine 
these assumptions. 
Contextual validity of data 
As Ingenerf nicely summarises, in health informatics, the problem of providing meaning to 
data communicated and then processed is the issue of semantic interoperability [18]: when 
communicating, healthcare professionals are used to interact dynamically at a syntactic and 
semantic levels until they have a common understanding. When dealing with a patient case, a 
physician creates and tests a mental image while interpreting data into information, based on 
his entire professional context, and it is within this context that he/she communicates. The 
risk of electronic data transfer is to lose the context by ‘lifting the ink off the paper’. Thus, 
the challenge is to ensure that context is faithfully carried with the data and information 
transferred. The physical reality, the clinician’s mental model, and the information model 
embodied in the electronic health record (EHR) or data exchange may be three or even four 
quite different things [19, 20]. 
In 1991, Johan van der Lei spoke and wrote adamantly against the misuse of data in 
computer-stored medical records and formulated the First Law of Medical Informatics: “Data 
shall be used only for the purpose for which they were collected” [21] with the explicit 
consequence that “If no purpose was defined prior to the collection of the data, then the data 
should not be used.” Van der Lei gave two major reasons for this: a) the quality of the data, 
and b) the context of the data. Given advances in technology, the challenges to elicit and 
process such data are now quite tractable, at least in Western countries, and there is an 
increasing demand to exploit this data. So, we have to look carefully at and beyond the two 
barriers mentioned by van der Lei, with a focus on the fundamental principles applying to re-
use of data and information. Perhaps it is time to re-formulate the First Law with words such 
as “Usage of data for purposes other than those for which they were generated is acceptable 
only when this has been validated stringently according to both ethical and scientific 
principles, including faithful reflection of context.” The ethical validation should include 
consideration of the potential socio-economic benefit, but also that patient concerns about 
data misuse can contribute to “censored” EHR content [8]. 
Assumptions about data quality and provenance 
There is a general organisational context and a specific clinical context of stored clinical data. 
Transferability is a very real and serious issue, for at least the following two reasons: 
analytical variation and biological variation. For example, even if a laboratory test has the 
same name in two clinical locations, the analytical methods may not be identical, and hence 
the data generated may vary significantly. The problem of transferability was investigated by 
many research groups in the 1980s and 1990s. For instance, the impact of various factors, 
when considered individually, on the validity of the outcome of decision support systems 
(e.g. technology, methodology, and terminology factors) was clearly demonstrated [22].  For 
instance, the study showed that even for international standard clinical protocols there are 
differences in the local interpretation of the meaning of individual clinical signs and 
symptoms. There can be variation in the nosology: the state of knowledge with regard to the 
investigation or classification of the clinical problem(s) under examination, co-morbidities, 
previous clinical history, interventions, and drugs taken. There may even be cultural 
differences in clinical practice and technologies applied or differences in the common 
language [22]. Our conceptual understanding and interpretation of ‘disease’ changes over 
time, as does diagnostic capability, treatment and care regimes, technical and pharmaceutical 
abilities, and political governance. Therefore, a technical solution to the problem of 
interoperability at a semantic level, for instance in terms of standardised terminologies, is 
merely a partial solution.  
Justification of inferences: scientific and technological advances 
Uncritical secondary use of data from medical records based on blind trust in the semantic 
interoperability of such data is irresponsible. Such unconstrained secondary usage of data 
could for instance erroneously extrapolate a pharmaceutical drug trial based on a cohort of 
single illness young to middle-aged men to a very different context such as prescribing the 
drug to small children, postmenopausal or aged women, or people with co-morbidities.  The 
suitability of the knowledge drawn into the new setting needs to be assessed as to its context 
and origins to decide if it is applicable to the setting, including what verification, adjustments, 
or safety parameters are needed.  
Epidemiological differences may to some extent be compensated for by normalisation 
procedures. Terminological differences may be coped with by standardization and mapping, 
which has required decades of sustained efforts and funding. A recent example was the 
Observational Medical Outcomes Partnership (OMOP), which developed a common data 
model to support analysis of heterogeneous data from operational EHRs, adverse incident 
reports, and financial claims [23]. Methodological differences and differences with respect to 
analytical quality may also sometimes be compensated for by normalisation procedures. Such 
calculations are feasible when one knows the exact correlations and the valid context for 
interpretation, but may also be accomplished according to the local reference intervals at the 
point of the clinical intervention. 
Scientific efforts have been made in large European Union Research and Development (EU 
R&D) projects as well as in smaller national projects to combine and exploit the merge or 
comparison of clinical data from several databases from various countries. The EU-ADR 
project used normalisation to score clinical events and the PSIP project used a crude 
normalisation of laboratory data (relative to a population mean) but did not merge the various 
databases [24].  
It is feasible to provide a solution through a structured definition of the necessary amounts of 
details for each element within the context in order to enable valid usage of data. The means 
is meta-data, meta-information and meta-knowledge for each individual datum, information, 
and piece of knowledge applied [25, 26]. Such required data, information, and knowledge 
exist, but they are distributed, and unfortunately constitute a large but necessary overhead at 
the secondary use processing. 
The state of the art in the technological aspects of secondary use of data is progressing 
rapidly. The astonishing potential of digital technology to offer high-quality, high-volume, 
routine data to generate a virtuous circle of data-driven quality improvements to both direct 
patient care and secondary uses to support operational management, public health, and 
research has stimulated massive investment [27]. A promising example is the “Green Button” 
project, which aims eventually at offering real time EHR cohort analysis to provide decision 
support for the many cases where gold standard randomized control trial (RCT) evidence is 
lacking [28, 29]. The Patient Centred Outcomes Research Institute (PCORI) promotes the 
development of methodological standards for research that can enhance the development of 
evidence –based patient-centred health [30, 31]. The approach is founded on a systematic 
process involving public comment, engagement, and revision. The aim is to promote research 
that is scientifically sound, meaningful, and patient-centred. This approach parallels many of 
the developments in precision medicine, which can be defined as prevention and treatment 
strategies that account for individual variability [32].  The applicability of precision medicine 
has increased dramatically with the development of large-scale biologic databases involving 
genomics, proteomics, and metabolomics, along with the computational tools for dealing with 
this data.  Major developments in patient centred outcomes research and precision medicine 
are in turn underpinned by major works to ensure patient consent (e.g., the Data 
Segmentation for Privacy– DS4P initiative) [33] and patient safety monitoring (e.g., work on 
establishing common formats to allow for the uniform collection and reporting of patient 
safety data by patient safety organisations) [34]. 
It may be that current developments with machine learning using previously unimaginable 
levels of computational power and quantities of diverse but linkable data will leapfrog 
traditional approaches to the issues described here (at least the technical ones) [35], but it 
seems premature to yet regard this as a foregone conclusion or a comprehensive solution. 
 
4. Evaluation aspects in national and regional policy 
OECD findings 
The overall ambition of OECD member states is to better include e-health into their health 
policies and better align e-health investments to health needs [11]. Already in 2012, most 
OECD countries participating in an OECD study [36] reported a national plan or policy to 
implement EHRs (22 of 25 countries). Most had also begun to implement that plan (n=20) 
and a majority (n=18) had included some form of secondary use of EHRs within their 
national plan. The most commonly included secondary uses were public health monitoring 
and health system performance monitoring (n=15). Half of the countries also indicated that 
their plans included that physicians could query the data to support treatment decisions. The 
least commonly reported planned data use was for facilitating or contributing to clinical trials 
(n= 10). Regular use of EHR data for secondary analyses was already underway, mainly for 
public health monitoring (n=13) and general research (n=11) [36].  
Key elements in evaluation from the viewpoint of secondary use of health data 
As noted above, an important prerequisite for secondary use of personal health data is the 
transferability of data, which requires organizational, technical, semantic, and legal 
interoperability, as well as quality and protection of personal data [37-39]. As countries 
develop and implement their e-health strategies, they will need to monitor progress to ensure 
that these requirements are met and that the e-health efforts are indeed contributing to health 
policy goals. For example, the EU e-health action plan section on global collaboration [40] 
stated that from 2013 the Commission should enhance its work on data collection and 
benchmarking activities in health care with relevant national and international bodies to 
include more specific e-health indicators and assess the impact and economic value of e-
health implementation. Close collaboration with the OECD and other actors is required to 
harmonize e-health indicators, including the OECD work on indicators for availability and 
usage of e-health [41] and the Nordic e-health indicator work [42], which has defined some 
common Nordic indicators also for interoperability, protection and quality of the personal 
health data – key elements in evaluation from the secondary use viewpoint. From the 
methodological viewpoint, triangulation of methods is needed to be able to cover all the 
aspects required by the use of personal health data. 
5. Examples: Using routine clinical data for HIT evaluation and quality indicators 
We now turn to practical examples of evaluation based upon secondary uses of data. The 
increasing uptake of EHRs and other health information systems has made routine collection 
and analysis of clinical data to evaluate and improve clinical performance an easier and faster 
undertaking. Furthermore, this provides opportunities to create a fine-grained picture of 
systems’ effects on quality of care by analysing interaction data that are a by-product of their 
use [43]. This section discusses two examples of how routinely collected data can be used to 
evaluate clinical performance, and how routine clinical and interaction data can be synergized 
to study the mechanisms of health information systems in detail and optimize their efficacy. 
Re-use of routinely collected clinical data to systematically evaluate clinical performance 
Health professionals need measures to judge the quality of care they provide in order to 
identify areas for improvement. Further, due to societal pressure on transparency and 
accountability, governments, accreditation organizations, patient associations and insurance 
companies have tremendously increased the amount of quality indicators to be measured. The 
current number of quality indicators make their manual calculation impracticable. Besides 
being time-intensive, causing registration burden and lack of timeliness, manual calculation is 
also error-prone and can jeopardize the reproducibility, validity, and comparability of quality 
measure results [44]. Therefore, quality indicators should be automatically calculated from 
routinely collected data from EHRs. 
Quality indicators are often compared over time and among health care institutions or care 
providers to identify outliers which require quality improvement activities. Results of these 
benchmarking activities can have large negative consequences for those who underperform in 
terms of financial restrictions imposed by insurance companies, loss of faith by patients, and 
loss of motivation by care providers. Aspects such as reproducibility, validity, and 
comparability of quality indicators are hence of utmost importance. However, these aspects 
are hampered by the fact that quality indicators are often ambiguously defined in natural 
language which impedes their automated computability. Therefore, quality indicators should 
be formalized before their release and application on routinely collected data from EHRs. The 
CLIF method developed by Dentler et al. [44] transforms quality indicators—which are 
typically described in unstructured text—into precise queries that can be computed on the 
basis of routinely collected clinical data. The method includes eight steps to formalize the 
nominator and denominator of a quality indicator and ensures that the formalizations obtained 
faithfully represent the meaning of the indicator. During the first step, the clinical concepts 
such as diagnoses and procedures are extracted from the text describing the quality indicator. 
These concepts need to be coded by standard terminologies such as SNOMED CT or ICD-
9/10 depending on the used national coding system. During the second step, these concepts 
are bound to concepts in the EHR’s underlying information model. In step three, the temporal 
aspects (e.g. a procedure should be performed before another procedure) of the indicator are 
formalized. Step four formalizes numeric criteria (e.g. HbA1c value must be below 53 
mmol/mol). In steps five and six, the Boolean criteria (e.g. three codes for Diabetes are 
combined with OR) are formalized and grouped. Step seven formalizes the exclusion criteria 
and negations, and in step eight criteria that only aim at the numerator and not to the 
denominator are identified. The generalizability and reproducibility of CLIF has been 
positively evaluated [44, 45]. Whilst CLIF may not directly solve re-use challenges such as 
missing data and poor data quality, it can guide implementation of local EHRs with respect to 
how clinical data items should be collected to increase data quality. 
Unobtrusive quantitative process evaluations to optimize health information systems 
Formalised quality indicators and guidelines are presented in electronic health information 
systems such as clinical decision support (CDS) and audit and feedback (A&F) systems. 
These systems have been moderately successful at ensuring that patients receive improved 
care, but their effectiveness is highly variable [46, 47]. CDS provides clinicians with case-
specific advice at the point of care (e.g., alerts or reminders) [48], whereas A&F provides 
population-level performance feedback on quality indicators over a period of time [46]. The 
reasons for their variable effectiveness are unclear because the mechanisms behind A&F’s 
success or failure are poorly understood [49]. This limits the ability to design better 
interventions [50]. The electronic nature of modern A&F systems allows for new possibilities 
to study the mechanisms of A&F quantitatively and unobtrusively by harnessing data that are 
routinely captured as a by-product of using the systems in real-life [43].  
Exploring the mechanism through which interventions bring about change is crucial to 
understanding both how the effects of the specific intervention occurred and how these 
effects might be replicated by similar future interventions [51]. Coiera [19] describes this 
mechanism as an information value chain that connects the use of a system to health 
outcomes. The chain begins with a user interacting with a system, and some of these 
interactions will provide information. Some of this information may cause the user to change 
her decision, which in turn can change the process of care. Finally, only some process 
changes affect health outcomes. For example, suppose that a general practitioner prescribing 
non-selective beta-blockers in a patient with asthma is alerted by a CDS system that this may 
cause exacerbations (“interaction”). When the general practitioner notices the alert 
(“information received”) and decides to cancel the prescription (“decision changed”) this will 
affect the patient’s medication regimen (“care process altered”) and can ultimately reduce the 
risk of asthma exacerbations and unscheduled hospital admissions (“outcome changed”). 
Whereas most A&F studies only investigate the relationship between exposure (i.e., inviting 
health professionals to interact with the system) and care processes or outcomes (stage 4 and 
5), electronic health information systems can produce usage logs that allow us to evaluate the 
relationships between all other stages in the information value chain, often with high fidelity 
[43]. Using measurements from all those stages can provide a more comprehensive picture of 
the intervention process to help explain the observed variability in its effectiveness. In fact, 
analysing the number and types of events in each stage may help to identify obstructions in 
the chain that withhold value from progressing to the subsequent stage, and reveal the 
determinants for a successful progression. However, we would like to emphasize that we are 
not arguing that analysing the information value chain makes qualitative process evaluations 
obsolete. Whereas a quantitative approach will reveal that certain events occurred (e.g., users 
declining an alert), a qualitative approach is more suitable to explore why these events 
occurred (e.g., the alert conflicted with patient preferences). Our vision is that quantitative 
evaluations may discover gaps in the intervention process which may then be filled in by 
qualitative work, making them complementary. 
6. The need for multi-level evaluation – key evaluative criteria  
Health systems, and their supporting technologies, should continuously learn and improve, as 
postulated by the Learning Health System approach [3], and thus evaluation of the means and 
processes of secondary use of health data is vital as being essential good practice. Particular 
foci of evaluation should be:  i) the consumers of secondary analysis of health data (e.g., 
health care managers, policy makers, clinicians, researchers, therapeutics developers, and 
society as ultimate beneficiary of better services); ii) considerations related to the utilisation 
of the secondary use of data; and iii) ensuring the validity and quality of the secondary use of 
clinical data [52]. 
Consumers of the secondary analysis of health data 
Health care is increasing in its complexity – not only is there a growing prevalence of multi-
morbidity (neonates surviving with on going health conditions; ageing populations with 
greater hazard of health events) but also increased specialisation of service delivery which 
can lead to fragmentation. Secondary use of data based on robust data linkage techniques has 
the potential to improve our understating of the breadth and course of health care delivery 
[53]. But while the secondary use of data continues to expand into a fast growing industry, 
there are important concerns about whether consumers are sufficiently aware of what is going 
on. For instance, is there a sufficient public awareness [2] of the benefits and challenges 
associated with secondary use of data?  
The utilisation of health system data is a sensitive community topic.  Any mistrust or lack of 
confidence about the way that data is handled could inhibit its application and severely affect 
its utilisation [54]. Major questions about the use of secondary data in health [2] continue to 
revolve around whether patients have the right to audit or place constraints on the use of their 
data. How does society ensure that the use of secondary data is transparent and is 
safeguarded? Several countries (e.g., Australia and the United Kingdom) are considering 
“opt-out” models of data consent which provide patients with right to opt out of their 
personal information being used for purposes beyond their direct care, but this may well lead 
to bias, for instance by social group or by health condition. This right is also reversible [54]. 
These issues relate very strongly to public trust, which we described in section 2 of this 
contribution.   
The secondary use of health system data relies upon some key principles including 
transparency and coordination with all stakeholders [55].  It also involves the establishment 
of mechanisms that can monitor, detect, and report on the application of knowledge derived 
from secondary use of health data (including any adverse incidents) and help to enhance its 
impact [56].  
Considerations related to the utilisation of secondary use of data 
The increasing availability and accessibility of large volumes of data from clinical and non-
clinical sources have helped to broaden the scope and utilisation of secondary health system 
data [57]. The technological ability to merge, link, re-use, and exchange data has outpaced 
the establishment of policies, procedures, and processes that monitor the ethics and legality of 
secondary use of data [2]. Types of data brought into integrational secondary analysis may 
include: 
o Web and social media data (Twitter, Facebook etc.) 
o Machine to machine data (sensors, vital signs etc.) 
o Biometric data (genetics, medical images, etc.) 
o Human-generated data (e.g., EMRs) [58] 
These data can be clinical or non-clinical [57]. Common clinical repositories may include 
data from EHRs and disease registries which are used to monitor patient care.  These may be 
linked to administrative records and other non-clinical sources such as data from over-the-
counter medications, finance, and other consumer data sources.  These various sources and 
types of data come each with their own nomenclature and definition e.g, de-identified data, 
anonymised data, reversible anonymised data, etc. [2] 
The conceptual framework for secondary use of health system data analytics is similar to, and 
can be based in part on, traditional health informatics processes such as the de-identification 
and anonymisation of data [2]. But there are also some important additional conceptual 
(architectural) considerations. In most cases, the user interfaces of traditional analytical tools 
differ from those used by “big data” which involve different informatics skills often requiring 
the use of open-source tools to address complex issues related to the retrieval, pooling, 
processing, and warehousing of data. These tools currently lack the support and the user 
friendliness of traditional analytical packages [58].   
Ensuring the validity and quality of secondary use of clinical data 
In the past, large silos of traditional paper records remained dormant and were seldom 
analysed, which meant they played little to no role to enhance the effectiveness and safety of 
health care [57].  Important methodological considerations to ensure that the product of the 
secondary use of health data is valid, reliable, and applicable, must involve: 
o Consideration of the quality of data 
o Understanding context to ensure that meanings inferred from the data are not 
distorted 
o Promoting transparency and governance [59] 
The discipline of health informatics has been built in large part on optimising key standards 
and considerations for data quality and data metrics [60-62].  These include consideration of 
the: 
o Accuracy of data  
o Data comparability 
o Data completeness 
o Data consistency 
o Data relevance 
o Data usability 
o Data validity 
The translation of data from secondary analysis into reliable and applicable knowledge that 
can be use to enhance the quality of care relies also on the proper and effective choice of 
study design.  Large data sources may enhance the potential for evaluation but they are still 
dependent on the formulation of robust evaluation questions and topics, as well as the proper 
study design and the use of appropriate tools to support rigorous measurement and 
assessment [63-66]. 
Methodological frameworks for secondary uses 
One framework for secondary use is SPIRIT (Systematic Planning of Intelligent Reuse of 
Integrated Clinical Routine Data), a best-practice framework and procedure model for the 
systematic planning of intelligent reuse of integrated clinical routine data [67]. Unlike other 
methods that concentrate on the analysis part, such as the KDD process (Knowledge 
Discovery in Databases) as proposed by Fayyad et. al. in 1996 [68] or OLAP (OnLine 
Analytical Processing) as proposed by Codd in 1993 [69], SPIRIT allows a holistic view of 
secondary use and supports the structured, stepwise planning and conduct of secondary use of 
clinical data in heterogeneous environments, with a special focus on the objectives of data 
analysis and supporting reproducibility of data analysis. Its application can and should be 
evaluated in various ways. 
First, after secondary data analysis, project management should evaluate whether the defined 
goals of secondary data reuse have been fulfilled. Often, we can find a scope creep, i.e. a 
change in originally intended goals to other or additional goals. This is not bad in itself, but 
should be made transparent.  How can this evaluation be done? One approach is to evaluate 
whether the generated reports respond to the originally defined goals. 
Second, the acceptance by stakeholders should also be evaluated: how do various 
stakeholders see the information and reports that are derived from secondary data analysis? 
Do they find them helpful? Do they use them regularly? Do they do a continuous reporting? 
Are there unexpected or adverse effects of secondary use of clinical data, e.g. changes in 
processes with the sole aim to optimize reported indicators? This evaluation assesses whether 
the chosen indicators of secondary data analysis respond to stakeholders’ needs and fulfil 
defined goals.  
7. Conclusion 
In conclusion, it can be postulated that while analysis of “Big data” is politically sexy and 
attracts funding, nonetheless it needs serious evaluation and evidence-based thinking. As with 
all health informatics activities and innovations, to do less – and thus condone imperfect or 
erroneous outcomes – would be unethical [70]. This should be based not just on data science, 
but also on broader evidence-based health informatics considerations that are needed to build 
and underpin trust and ensure feasibility and policy effectiveness. 
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